Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why? -- Ignore unavailable to you. Want to Upgrade?

To: goinbrk who wrote (382)	1/7/1999 11:44:00 AM
From: polar bear	Read Replies (1) \| Respond to of 455

Who is BIOSYN?? The press release copied below indicates another company, Biosyn, is developing a very similar product. Procept needs to clarify how their microbicide might be better that this one!!! I had hoped PRCT would have a niche to exploit! PRCT better get moving with their PRO2000. They have been too quiet!! Biosyn announces phase I trials of anti-HIV microbicide gel WESTPORT, Jan 07 (Reuters Health) - Patient enrollment in a phase I trial of the vaginal microbicide gel glyminox (SAVVY), used to prevent pregnancy and the transmission of HIV and other sexually transmitted diseases, has begun at the University of Pennsylvania Medical School, according to a Biosyn, Inc. press release. The safety and efficacy of the Philadelphia-based company's glyminox vaginal gel will be compared with that of nonoxynol-9, the leading topical contraceptive. According to Biosyn's president and CEO Anne-Marie Corner, this study represents a "...step toward the approval of a product that will give women the ability to protect themselves from acquiring sexually transmitted diseases. This would help to satisfy a huge unmet need for millions of women around the world." The use of microbicides to prevent HIV transmission is gaining support of the US government, health organization and AIDS researchers, the release continued. Company officials expect to receive market approval of their product for use as a contraceptive by 2001, and as a prophylactic for HIV and other STDs by 2002. The company is planning other studies, which will investigate the safety and efficacy of this product when used against chlamydia and gonorrhea.